Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TU2218 |
Synonyms | |
Therapy Description |
TU2218 inhibits VEGFR2 and TGFBR1 (ALK5), which potentially results in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 5538). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TU2218 | TU-2218|TU 2218|NCE 401|NCE401|NCE-401 | TGFBR1 inhibitor 16 VEGFR2 Inhibitor 37 | TU2218 inhibits VEGFR2 and TGFBR1 (ALK5), which potentially results in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 5538). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05204862 | Phase Ib/II | TU2218 TU2218 + unspecified PD-1 antibody | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |